Erratum to: Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis

Abstract

[Erratum to: BMB Reports 2025; 58(3): 140-145, PMID: 39757202, PMCID: PMC11955732] The BMB Reports would like to issue a correction to an article published in BMB Rep. 58(3): 140-145, titled "Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis". The original acknowledgment contained incorrect grant information. This has now been corrected at the authors' request as follows: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1 A6A3A11930589, NRF-2016R1A6A3A11934500, NRF-2016 R1D1A3 B03931646, NRF-2019R1I1A1A01057738, NRF-2019R1l1A3A01060016, NRF-2019R1l1A1A01060116, and RS-2023-00248058). It was also supported by the Chungnam National University Hospital Research Fund 2021 (2021-CF-033). Specifically, the grant number has been updated from 2016 (2016-CF-003) to 2021 (2021-CF-033). The authors apologize for any inconvenience or confusion this error may have caused. The ACKNOWLEDGEMENTS section in the original PDF version has been updated accordingly.